In postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions in their risk of a vertebral fracture compared to placebo, research shows.
Source: Science Daily
In postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions in their risk of a vertebral fracture compared to placebo, research shows.
Source: Science Daily